RBC Capital Markets and Biotech

Selected healthcare news for the capital firm - RBC Capital Markets, and the healthcare topic - Biotech. We have 50 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
10/4/2021 Get Ready for a Biotech M&A Comeback | Chief Investment Officer Biotech buyouts ebb and flow, and the space has been in ebb mode for a while now. But RBC Capital Markets sees a revival happening. Mergers and acquisitions (M&A) will be strong as large pharma companies seek to replenish their innovation portfolios with the cutting-edge science from small outfits, predicts Brian Abrahams, RBC managing director and co-head of biotechnology equity research .A recent spate of announced multi ...
8/10/2021 11 Biotech Companies Primed to Become Active M&a Acquirers Business Insider ... Insider subscribers. Become an Insider and start reading now. It's been a quiet year for drug-industry mergers and acquisitions. Biotechs that used to be active acquirers have been bought by larger pharma players. Insiders ... has been such a quiet year for M&A that RBC Capital Markets analysts tallied just $36 billion worth of transactions. For comparison, since 2018, drug companies have spent an average of $56 billion on ...
6/1/2021 FDA Biogen Decision Is High Stakes for All Biotech Stocks. Here's Why. | Barron's Dreamstime Before next Tuesday, the U.S. Food and Drug Administration will announce its final decision on whether to approve aducanumab, the Alzheimer‚Aos disease drug developed by Biogen . The decision, the most anticipated from the FDA in recent memory, will likely move not only Biogen shares, but shares of stocks across the biotech and biopharma sectors.In a note out early Tuesday, RBC Capital Markets analyst Brian Abrahams lays out ...
4/9/2021 Biotech Stocks Could Use A Win — Will The First Quarter Offer That? | Investor's Business Daily Gilead Sciences ( GILD ), Biogen ( BIIB ) and Vertex Pharmaceuticals ( VRTX ) could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday.X The prediction comes amid a broad correction for biotech stocks ... generate a bounce back after biotech's recent much-needed correction," RBC Capital Markets analyst Brian Abrahams said in a report to clients.Despite expectations for a soft first quarter, Abrahams sees "a number of compelling ...
3/29/2021 Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts FiercePharma Bluebird bio and partner Bristol Myers Squibb have outrun Johnson & Johnson and Legend Biotech in snagging the first FDA nod for a BCMA-targeted CAR-T therapy. But the label of the new drug, dubbed ... myeloma expert at ‚Aua leading academic center‚Au interviewed by RBC Capital Markets earlier this month was expecting a broader label that would allow patients to take the CAR-T therapy after failing just two ...
3/25/2021 Biotech Is Sliding, so Stock Picking Is Key, Analyst Writes | Barron's Potential action by both regulators and legislators could hit the sector. Dreamstime Biotech stocks have slid sharply this week, with the SPRD S&P Biotech ETF (ticker: XBI) falling 5.8% on Tuesday, 5.1% on Wednesday, and another 1.1% in premarket trading Thursday morning.So what gives? In a note out Thursday, RBC Capital Markets analyst Brian Abrahams wrote that the regulatory environment could be getting tougher for the sector. His ...
1/11/2021 Gilead Says Sales of Covid-19 Antiviral Beat Expectations as Pandemic Worsened | Barron's Gilead Sciences stock has fallen since remdesivir received emergency-use authorization from the FDA. Justin Sullivan/Getty Images The biotech company Gilead Sciences said that higher-than-expected sales of its Covid-19 antiviral remdesivir ... between $2.8 billion and $2.83 billion.In a note Monday, RBC Capital Markets analyst Brian Abrahams calculated that sales of Veklury in the fourth quarter alone were $1.9 billion, roughly twice his estimate of $1 ...
12/22/2020 4 Biopharma Stock Picks From Analysts for 2021 | Barron's Sarepta is a name that‚Aos favored by analysts at Citigroup and RBC Capital Markets. Dreamstime No industry has been watched as raptly this year as health care, as drug developers raced to deliver us ... lifted the diagnostics subsector 31%, while clinical labs rose 18%. Biotech stocks were up 13%, but traditional pharmaceutical stocks and hospitals gained a mere 3%. Retail pharmacies, meanwhile, sank 18%.Read MoreFutures Fall Slightly ...
12/22/2020 4 Biopharma Stock Picks From Analysts for 2021 Sarepta is a name that‚Aos favored by analysts at Citigroup and RBC Capital Markets.DreamstimeNo industry has been watched as raptly this year as health care, as drug developers raced to deliver us ... lifted the diagnostics subsector 31%, while clinical labs rose 18%. Biotech stocks were up 13%, but traditional pharmaceutical stocks and hospitals gained a mere 3%. Retail pharmacies, meanwhile, sank 18%.As a group, health-care ...
12/16/2020 Gilead guts its filgotinib plans, dealing a blow to O'Day's diversification dream FiercePharma ... Sciences has decided to cut its losses on filgotinib, once a blockbuster hopeful and the poster child of the Big Biotech‚Aos early effort to diversify from its core antiviral portfolio.Gilead has scrapped most ... Leerink analyst Geoffrey Porges said in a Wednesday note. And RBC Capital Markets analyst Brian Abrahams, in a Tuesday note, labeled the deal adjustment as ‚Auan effective, albeit unsurprising, end to the high-opportunity promise ...
12/7/2020 Race for Multiple Myeloma Drugs Not Moving Stocks ‚Äî Yet | Barron's ... as BCMA. They include: Bristol Myers Squibb (ticker: BMY), working with bluebird bio (BLUE); Johnson & Johnson (JNJ), working with Legend Biotech (LEGN); Allogene Therapeutics (ALLO); Regeneron Pharmaceuticals (REGN); and Amgen (AMGN).In Monday trading, investors ... but we think there is space for multiple players,‚Au RBC Capital Markets analyst Luca Issi wrote in a Sunday note. He hopes that the different ways the BCMA treatments are delivered will lead to ...
10/21/2020 A Crucial FDA Hearing Looms for Biogen Alzheimer's Drug. Here's What's at Stake. ... efforts of science to change the awful course of the illness. And Biogen has the scars to prove it.The biotech company concluded that it was futile to continue its clinical trial of an antibody ... rating by the analysts tallied at FactSet is a Hold.RBC Capital Markets analyst Brian Abrahams is representative of those with a neutral view of the stock. On Friday, he hosted a mock advisory committee ...
9/24/2020 M&A wrap: IPO update, Paul Hastings, Peter Thiel, LinkedIn, Richard Branson, UnitedHealth, KKR, 1-800 Contacts, Compass Diversified, TH Lee Print Register now Life sciences and biotech issuers, along with special purpose acquisition companies, dominated the first-half 2020 IPO market, according to a report from Paul Hastings. SPACs have accounted for nearly half of ... organization and provider of advanced pharmaceutical technologies, from TPG Capital. RBC Capital Markets and Kirkland & Ellis advised the buyers. Debevoise & Plimpton advised the sellers. Odyssey Investment Partners is buying ProPharma Group from Linden Capital Partners ...
8/11/2020 Roche's low-price Evrysdi will take 'meaningful' SMA share from Biogen's Spinraza: analyst | FiercePharma FiercePharma ... Spinraza at a high, investigative maintenance dose of 28 mg, compared with the FDA-approved 12 mg dose. The Big Biotech also just launched the Respond trial, aiming to find out whether Spinraza can benefit ... about $382,500, Foroohar noted. Evrysdi’s price was “slightly surprising” to RBC Capital Markets analyst Brian Abrahams, who previously estimated that Roche would go with a sticker of about $400,000. The reason? Mainly because payers told ...
7/31/2020 Gilead banks on blockbuster remdesivir with sunnier 2020 outlook FiercePharma ... long list of drugmakers that have suffered from business slowdowns caused by COVID-19. But unlike its peers, the Big Biotech has an unexpected blockbuster source of revenue that led it to elevate its full ... Dickinson told investors during a conference call on Thursday. By RBC Capital Markets analyst Brian Abrahams’ calculation, that roughly equates to $3.5 billion in additional second-half 2020 sales of the antiviral. Gilead's previous guidance ...
7/30/2020 BMS, bluebird refile FDA approval application for CAR-T therapy in myeloma - MedCity News MedCity News ... the time that they intended to resubmit their application by the end of July. In a note to investors Wednesday, RBC Capital Markets analyst Luca Issi wrote that bluebird had confirmed that it requested a ... a market worth $20 billion, with Johnson & Johnson and Legend Biotech’s BCMA-targeting CAR-T, JNJ-4528, planned for FDA submission by the end of the year. In addition to ide-cel and JNJ-4528 ...
7/28/2020 Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst FiercePharma ... incorporates “public health requirements during the pandemic,” she said. Pfizer's deal also includes an option for another 500 million doses, RBC Capital Markets analyst Randall Stanicky pointed out, so "investors are increasingly seeing real opportunity ... remains to be seen how Moderna will approach pricing. The biotech on Monday received another $472 million in R&D funding from the U.S. government, taking its total to about $955 million. Moderna and Pfizer ...
7/16/2020 BioSpace Movers & Shakers, July 17 | BioSpace BioSpace ... biotech and pharma companies globally. He also served as board president at Biotech Partners and as managing director, biotechnology analyst at Credit Suisse, RBC Capital Markets and WR Hambrecht + Co. Cerevel Therapeutics –Kathleen W. Tregoning was named chief corporate affairs officer for Boston-based Cerevel. Tregoning brings more than two decades of healthcare experience leading external engagement, strategy and policy initiatives across both the public and private sectors. In this ...
7/8/2020 In a test for Hahn's FDA, Biogen submits controversial Alzheimer's drug aducanumab | FierceBiotech FierceBiotech It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab, the once-failed Alzheimer’s drug it resurrected just in time ... trials” upon which the BLA rests. And Brian Abrahams of RBC Capital Markets sees a 30% chance that the FDA OKs aducanumab “despite the mixed ph.III data.” For its part, Biogen is bullish on the ...
6/18/2020 Judge wipes out Biogen's Tecfidera patent protections in suit against Mylan FiercePharma ... could wipe out years of monopoly sales. Webinar Produce Novel Biologics with High Purity, Quality and Yield In this Fierce Biotech webinar we will examine a number of the benefits of Lonza’s , XS® Pichia 2.0 ... she seemed to favor Mylan’s stance. As for next steps, RBC Capital Markets analyst Brian Abrahams sees an appeal taking about 12 months. In a note to clients before the decision, his team predicted a ...
6/10/2020 RBC Trade for the Kids charity event goes virtual PR Newswire Virtual celebrations held by RBC Capital Markets employees in Canada , the U.S., the U.K., Europe , Japan , Hong Kong , Australia , Barbados and Bahamas Donated US $4 million to 45+ charities worldwide 19 U.S. based charities: Autism Society of Texas ; Big Brothers Big Sisters of the Bay Area; Biotech Partners; Boys & Girls Clubs of Chicago ; Boys & Girls Clubs of Hudson County; Capital for Kids; Children of Fallen Patriots; Christopher House ; Comer Children's ...
6/8/2020 Report: AstraZeneca informally approached Gilead about potential merger - MedCity News MedCity News An AstraZeneca location in Gaithersburg, Maryland Britain’s largest drugmaker has expressed interest in acquiring a U.S. biotech company that recently received authorization to make a drug to treat Covid-19, according to a news report ... was completed last month. In a note to investors Monday, RBC Capital Markets analyst Brian Abrahams wrote that on the one hand, Gilead’s size and improving strategic direction could create hurdles to such a large ...
6/8/2020 SRPT Stock: Gene Therapy Beats Sarepta's Own Expectations | Investor's Business Daily ... children with muscular dystrophy continued to show functional improvements a year after receiving Sarepta Therapeutics ' ( SRPT ) experimental gene therapy, the biotech said Monday. In response, SRPT stock jumped. Researchers tested two doses of the gene ... The test results solidify Sarepta's leadership in treating muscular dystrophy, RBC Capital Markets analyst Brian Abrahams said in a report to clients. Sarepta is speeding ahead with a gene therapy for Duchenne muscular dystrophy. He ...
6/8/2020 Stocks Surge on Cocktail of Tailwinds: What Wall Street’s Saying - TheStreet TheStreet ... Neither side has confirmed ongoing talks currently. The deal would create a $170 billion — potentially more when accounting for synergies biotech giant — that could possibly create a virus vaccine efficiently and sell it at scale ... was Amazon ( AMZN ) - Get Report , up 1.8% on the day. RBC Capital Markets boosted its price target on the stock, saying the Coronavirus tailwind is creating a potentially sustainable accelerated consumer move into e-commerce ...
5/21/2020 Edited Transcript of ARMK earnings conference call or presentation 5-May-20 12:30pm GMT Yahoo News ... Merrill Lynch, Research Division - Associate in Equity Research Kevin Damien McVeigh Credit Suisse AG, Research Division - MD Seth Robert Weber RBC Capital Markets, Research Division - Equity Analyst Shlomo H. Rosenbaum Stifel, Nicolaus & Company, Incorporated, Research ... Aramark clients across the U.S. in the health care, pharmaceutical, biotech, medical device and other vital industries where employees rely on these supplies to perform their jobs. As we look to the future, our teams ...